BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 31909763)

  • 21. Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study.
    Pivot X; Verma S; Fallowfield L; Müller V; Lichinitser M; Jenkins V; Sánchez Muñoz A; Machackova Z; Osborne S; Gligorov J;
    Eur J Cancer; 2017 Nov; 86():82-90. PubMed ID: 28963915
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-minimization analysis of subcutaneous versus intravenous trastuzumab administration in Chilean patients with HER2-positive early breast cancer.
    Rojas L; Muñiz S; Medina L; Peña J; Acevedo F; Pinto MP; Sanchez C
    PLoS One; 2020; 15(2):e0227961. PubMed ID: 32023267
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Societal cost of subcutaneous and intravenous trastuzumab for HER2-positive breast cancer - An observational study prospectively recording resource utilization in a Swedish healthcare setting.
    Olofsson S; Norrlid H; Karlsson E; Wilking U; Ragnarson Tennvall G
    Breast; 2016 Oct; 29():140-6. PubMed ID: 27498127
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Subcutaneous trastuzumab (Herceptin) versus intravenous trastuzumab for the treatment of patients with HER2-positive breast cancer: A time, motion and cost assessment study in a lean operating day care oncology unit.
    Tjalma WAA; Van den Mooter T; Mertens T; Bastiaens V; Huizing MT; Papadimitriou K
    Eur J Obstet Gynecol Reprod Biol; 2018 Feb; 221():46-51. PubMed ID: 29245056
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Economic benefits of subcutaneous trastuzumab administration: A single institutional study from Karolinska University Hospital in Sweden.
    Hedayati E; Fracheboud L; Srikant V; Greber D; Wallberg S; Linder Stragliotto C
    PLoS One; 2019; 14(2):e0211783. PubMed ID: 30716137
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current situation and challenges regarding biosimilars in Japan: an example of trastuzumab biosimilars for breast cancer.
    Hara F; Tajima K; Tanabe K
    Future Oncol; 2019 Apr; 15(12):1353-1361. PubMed ID: 30767568
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands.
    Franken MG; Kanters TA; Coenen JL; de Jong P; Koene HR; Lugtenburg PJ; Jager A; Uyl-de Groot CA
    Anticancer Drugs; 2018 Sep; 29(8):791-801. PubMed ID: 29846248
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ABP 980: A Trastuzumab Biosimilar.
    Dhillon S
    BioDrugs; 2018 Oct; 32(5):511-514. PubMed ID: 30264234
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study.
    Zambetti M; Montemurro F; Morandi P; Zamagni C; Brandes AA; Bisagni G; Cagossi K; Bengala C; Gori S; Iannacone C; Stell A; Gianni L
    Eur J Cancer; 2018 Dec; 105():61-70. PubMed ID: 30396014
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer.
    Denys H; Martinez-Mena CL; Martens MT; D'Hondt RG; Graas ML; Evron E; Fried G; Ben-Baruch NE; Vulsteke C; Van Steenberghe MM
    Breast Cancer Res Treat; 2020 May; 181(1):97-105. PubMed ID: 32240454
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Budget Impact Analysis of the Introduction of a Trastuzumab Biosimilar for HER2-Positive Breast Cancer in China.
    Chai Q; Wen H; Lang Y; Zhang L; Song Y; Liu X
    Clin Drug Investig; 2022 Nov; 42(11):937-947. PubMed ID: 36115003
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of the trastuzumab biosimilar candidate CT-P6.
    Esteva FJ; Saeki T; Kim H; Stebbing J
    Future Oncol; 2018 Aug; 14(19):1909-1919. PubMed ID: 29482364
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical development of CT-P6 in HER2 positive breast cancer.
    Fu C; Stebbing J; Esteva FJ
    Expert Opin Biol Ther; 2019 Oct; 19(10):987-992. PubMed ID: 31507219
    [No Abstract]   [Full Text] [Related]  

  • 34. Is weight-based IV dosing of trastuzumab preferable to SC fixed-dose in some patients? A systematic scoping review.
    Kolberg HC; Jackisch C; Hurvitz SA; Winstone J; Barham H; Hanes V; Courmier D
    Breast; 2021 Jun; 57():95-103. PubMed ID: 33799233
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravenous versus subcutaneous trastuzumab: an economic and patient perspective.
    Mitchell H; Morrissey D
    Br J Nurs; 2019 May; 28(10):S15-S20. PubMed ID: 31116603
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Subcutaneous Trastuzumab: A Review in HER2-Positive Breast Cancer.
    Heo YA; Syed YY
    Target Oncol; 2019 Dec; 14(6):749-758. PubMed ID: 31686307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expanded access to anticancer treatments from conversion to biosimilar pegfilgrastim-cbqv in US breast cancer patients.
    McBride A; Alrawashdh N; MacDonald K; Abraham I
    Future Oncol; 2022 Jan; 18(3):363-373. PubMed ID: 34747185
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Total pathological complete response versus breast pathological complete response in clinical trials of reference and biosimilar trastuzumab in the neoadjuvant treatment of breast cancer.
    Stebbing J; Baranau Y; Manikhas A; Lee SJ; Thiruchelvam P; Leff D; Esteva FJ
    Expert Rev Anticancer Ther; 2018 Jun; 18(6):531-541. PubMed ID: 29580109
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential cost savings from chemotherapy-induced febrile neutropenia with biosimilar filgrastim and expanded access to targeted antineoplastic treatment across the European Union G5 countries: a simulation study.
    Sun D; Andayani TM; Altyar A; MacDonald K; Abraham I
    Clin Ther; 2015 Apr; 37(4):842-57. PubMed ID: 25704107
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost effectiveness of using trastuzumab biosimilars compared to trastuzumab original drugs to treat breast cancer in a hospital setting.
    Barat EC; Arrii MLE; Soubieux-Bourbon A; Daouphars M; Varin R; Tilleul PR
    Breast; 2023 Dec; 72():103588. PubMed ID: 37857129
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.